Microbot Medical Inc. (MBOT)
Company Description
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.
The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio.
It has 42 issued/allowed patents and 23 patent applications pending worldwide.
The company has a strategic collaboration agreement with Stryker Corporation for technology co-development.
Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.

Country | United States |
IPO Date | Mar 25, 1992 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 20 |
CEO | Harel Gadot |
Contact Details
Address: 25 Recreation Park Drive Hingham, Massachusetts United States | |
Website | https://www.microbotmedical.com |
Stock Details
Ticker Symbol | MBOT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000883975 |
CUSIP Number | 59503A204 |
ISIN Number | US59503A2042 |
Employer ID | 94-3078125 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Harel Gadot | Co-Founder, President, Chief Executive Officer & Chairman |
Dr. Simon Sharon MBA, MSc | Chief Technology Officer & GM of Microbot Israel |
Rachel Vaknin | Chief Financial Officer |
Dr. Juan Diaz-Cartelle | Chief Medical Officer |
Michal Ahuvia | Director of Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 01, 2025 | 8-K | Current Report |
Mar 31, 2025 | POS AM | Filing |
Mar 31, 2025 | POS AM | Filing |
Mar 28, 2025 | POS AM | Filing |
Mar 27, 2025 | POS AM | Filing |
Mar 27, 2025 | POS AM | Filing |
Mar 27, 2025 | S-3/A | [Amend] Filing |
Mar 25, 2025 | 10-K | Annual Report |
Mar 10, 2025 | S-3 | Filing |
Mar 04, 2025 | 8-K | Current Report |